BioCryst Pharmaceuticals, Inc. unveiled that the compensation committee of their board of directors provided six newly recruited employees with restricted stock units (RSUs) encompassing a total of 61,750 shares of BioCryst common stock. These RSUs were granted on May 1, 2026, to entice the employees joining the company. The grant aligns with Nasdaq Listing Rule 5635(c)(4).